Study of IBR733 Cell Injection in Acute Myeloid Leukemia

This is an open-label clinical study: phase Ia is the dose-escalation part, and phase Ib is the dose-expansion part. The phase Ia study is to evaluate the safety, tolerability, recommended phase II dose, pharmacokinetics, immunogenicity and preliminary efficacy of IBR733 cell injection in relapsed/refractory acute myeloid leukemia (AML).

Trial Details

NCT ID
NCT06234904
Phase
PHASE1
Sponsor
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • IBR733 Cell Injection
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Subjects volunteer to participate in this clinical study, are fully aware of the study and have signed the Informed Consent Form (ICF). Subjects ar…
  • Age: 18-74 (both inclusive), female or male.
  • Patients with AML (including secondary AML) diagnosed according to the WHO 2022 criteria.
  • Patients with AML who meet one of the following criteria: (1) Relapsed AML: reoccurrence of leukemia cells in peripheral blood or ≥5% blasts in bon…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →